CN108774641A - Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application - Google Patents
Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application Download PDFInfo
- Publication number
- CN108774641A CN108774641A CN201810637044.3A CN201810637044A CN108774641A CN 108774641 A CN108774641 A CN 108774641A CN 201810637044 A CN201810637044 A CN 201810637044A CN 108774641 A CN108774641 A CN 108774641A
- Authority
- CN
- China
- Prior art keywords
- expression
- lncrna
- heart disease
- coronary heart
- uc010yfd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related applications；Specifically, the application the present invention provides the reagent material and/or instrument and equipment of following lncRNA levels in sample of the detection from test individual in preparing the detecting system for diagnosis of coronary heart disease risk：ENST00000444488.1 and/or uc010yfd.1.The expression of ENST00000444488.1 increases, the expression of uc010yfd.1 declines, and test individual coronary heart disease risk increases.
Description
Technical field
The present invention relates to coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related applications, specifically,
The present invention relates to the lncRNA's of 7 differential expressions such as ENST00000444488.1 in sample of the detection from test individual
Application of the horizontal reagent material and/or instrument and equipment in preparing the detecting system for assessing coronary heart disease risk, also
It is related to a kind of detecting system of assessment incidence of coronary heart disease risk.
Background technology
Coronary heart disease (coronary artery disease, CAD) is the first fatal disease in global range, including its
In with serious complicated famous acute myocardial infarction (acute myocardial infarction, AMI), be to lead to global people
The main reason for mouth morbidity and death.《Chinese cardiovascular disease report 2017》Report display, China's CAD illness rates are total within 2013
It has been the ascendant trend since Chinese cities in 10.2 ‰, 2015 and rural resident's coronary heart disease death rate continue 2012.Although close
In a little year world wides, prevention, drug and the intervention policy aspect of coronary heart disease all have made great progress, but of cardiovascular disease
Body, medical treatment & health and social economical burden are still gradually aggravating, and situation allows of no optimist.Therefore, the diagnostic work of coronary heart disease is particularly
Important, in molecular biology level, screening biomarker will be helpful to better diagnose coronary heart disease, also can be to coronary heart disease
Pathogenesis and the new targeted therapy means of research be provided with and help positively.
Atherosclerosis is the principal pathogenetic mechanism of coronary heart disease, while being also a kind of chronic inflammatory diseases.Cardiovascular disease
The chronic dangers factor long-time stimulus blood vessel endothelium such as risk factor, including hypertension, dyslipidemia, smoking, excessive consumption of alcohol increases
Oxidative pressure induces inflammatory reaction, leads to Endothelial Dysfunction, promotes the generation of atherosclerosis；Subsequent foam cells shape
At, smooth muscle cell proliferation and to subendothelial migration, fibrous plaque is promoted to be formed；Inflammatory reaction aggravates, and leads to plaque rupture, blood
Bolt is formed, and acute coronary syndrome (acute coronary syndrome, ACS) is caused.Thus, atherosclerosis
Process is actually the complex process for the interaction that different type cell participates in, by different encoding genes and non-coding base
Because of regulation and control (Wierda, RJ, Geutskens, SB, Jukema, JW, et al., Epigenetics in atherosclerosis
and inflammation,J Cell Mol Med,2010；14:1225-1240).
Long-chain non-coding RNA (long non-coding RNA, lncRNA) be a kind of transcript length be more than 200nt and
The RNA molecule of albumen is not encoded, is guarded and is spent relatively low and there is species specificity.Multinomial research has shown that lncRNAs participates in such as cell
Transduction, chromosome modification, transcription and translational control and the pathogenetic biological processes of a variety of diseases, in atherosclerosis
Endothelial Dysfunction, Phenotypic Change of Smooth Muscle Cells, reverse cholesterol transport, foam wanshing and vascular inflammation etc.
All there is important regulating and controlling effect (Zhou, T, Ding, JW, Wang, XA, et al., Long noncoding RNAs and
atherosclerosis,Atherosclerosis,2016；248:51-61).Myocardial infarction is associated with transcript (myocardial
Infarction associated transcript, MIAT) be earliest identification AMI risk factors lncRNA, it is single
The expression that mononucleotide polymorphism site (Single Nucleotide Polymorphism, SNP) can change MIAT, causes
To neurological susceptibility (Ishii, N, Ozaki, K, Sato, H, et al., Identification of a the novel non-of AMI
coding RNA,MIAT,that confers risk of myocardial infarction,Journal of human
genetics,2006；51:1087-1099).Coronary heart disease genome-wide association study (genome-wide association
Studies, GWAS) display be located at 21 region of chromosome 9p be strongest coronary heart disease susceptibility regions (Helgadottir, A,
Thorleifsson,G,Manolescu,A,et al.,A common variant on chromosome 9p21affects
the risk of myocardial infarction,Science(New York,N.Y.),2007；316:1491-1493；
McPherson,R,Pertsemlidis,A,Kavaslar,N,et al.,A common allele on chromosome
9associated with coronary heart disease,Science(New York,N.Y.),2007；316:1488-
1491；Samani,NJ,Erdmann,J,Hall,AS,et al.,Genomewide association analysis of
coronary artery disease,The New England journal of medicine,2007；357:443-
453), this region includes NAINK4 antisense non-coding RNA ANRIL (antisense non-coing of a functional r
RNA in the INK4locus, ANRIL), to have the function of in cardiovascular disease direct regulation and control (Holdt, LM, Hoffmann,
S,Sass,K,et al.,Alu elements in ANRIL non-coding RNA at chromosome
9p21modulate atherogenic cell functions through trans-regulation of gene
networks,PLoS genetics,2013；9:e1003588).It is multinomial that researches show that ANRIL includes atherosclerotic process
In vascular endothelial cell, smooth muscle cell, macrophage, express in inflammatory cell and arteria carotis communis, cis regulatory target base
Cause promotes cell Proliferation, and Apoptosis, phenotype is inhibited to meet the performance of atherosclerosis.
To explain how lncRNA participates in the occurrence and development of regulation and control CAD, the systematically Recognition Different table in patients with coronary artery disease
The lncRNAs reached, screening have potential functionality lncRNA as biomarker, further explaining it in artery congee
Effect in sample hardening mechanism will be very necessary.It is based on classical symptom, electrocardiogram and myocardium calcium at present to the diagnosis of coronary heart disease
Albumen (cTnI and cTnT) is made, but these diagnostic methods all respectively have its limitation and deficiency.Therefore, new, sensibility is found
And the better biomarker of special row, coronary heart disease is diagnosed, is of great significance.
Invention content
It is an object of the present invention to find the biological marker of new, sensibility and the better diagnosis of coronary heart disease of special row
Object.
During inventor studies at one, by lncRNA/mRNA chip analysis, it is horizontal to obtain coronary heart disease full-length genome
LncRNA/mRNA express spectras include the mRNAs of lncRNAs and 890 differential expression of 1210 differential expressions.The present invention selects
The lncRNA of 7 differential expressions is taken：ENST00000444488.1,uc010yfd.1,ASO3973,
ENST00000602558.1, ENST00000561165.1, RNA147299_p0403_imsncRNA819 and
ENST00000415255.1, this 7 differential expression of repeated authentication in independent coronary heart disease case-control large sample
LncRNA, consistent with chip of expression spectrum result, wherein ENST00000444488.1 is significantly increased to 2.6 in CAD groups PBMCs
(P again<0.01), uc010yfd.1, ASO3973, ENST00000602558.1, ENST00000561165.1, RNA147299_
P0403_imsncRNA819 and ENST00000415255.1 is remarkably decreased in the PBMCs of CAD groups respectively to 37%, 81%,
79%, 87%, 83% and 65% (P<0.01).It is analyzed by ROC curve, 6 lncRNAs (ENST00000444488.1,
Uc010yfd.1, ASO3973, ENST00000602558.1, ENST00000561165.1 and RNA147299_p0403_
ImsncRNA819 AUC) is 0.599-0.799, the efficiency with certain diagnosis of coronary heart disease.Wherein
The AUC of ENST00000444488.1 and uc010yfd.1 is respectively 0.799 (0.762-0.837) and 0.779 (0.744-
0.815).The AUC of combination ENST00000444488.1 and uc010yfd.1 rises to 0.851 (0.819-0.884), sensitivity
It is 0.707, specificity 0.844 has higher diagnostic value.Therefore, ENST00000444488.1 and uc010yfd.1 can
Using as new lncRNA biomarkers；Further combined with age, the mould of tetra- BMI, blood glucose and HDL common risk factors
Type, ROC curve area AUC is up to 0.902 (0.876-0.928), susceptibility 0.736, specificity 0.922, therefore is somebody's turn to do
Model has higher diagnostic.412 patients with coronary heart disease of independent large sample include that 290 AMI patients and 122 are non-
AMI patient, compared with non-AMI, ENST00000444488.1 is expressed in AMI patient is significantly increased to 1.5 times, ROC curve point
The results show that its AUC is 0.758 (0.716-0.800), susceptibility 0.632, specificity 0.773 shows for analysis
ENST00000444488.1 has the efficiency of diagnosis AMI.
To, on the one hand, the application the present invention provides following lncRNA as the biomarker of diagnosis of coronary heart disease：
ENST00000444488.1 and/or uc010yfd.1.
On the other hand, the present invention also provides the reagent materials of following lncRNA levels in sample of the detection from test individual
The application of material and/or instrument and equipment in preparing the detecting system for diagnosis of coronary heart disease risk：
ENST00000444488.1 and/or uc010yfd.1.
Specific embodiment according to the present invention, ASO3973, ENST00000602558.1, ENST00000561165.1,
RNA147299_p0403_imsncRNA819 and/or ENST00000415255.1 can be used for assisting ENST00000444488.1
And/or the further diagnosis of coronary heart disease of uc010yfd.1.
Specific embodiment according to the present invention, lncRNA levels include expression in peripheral blood mononuclear cells.
Specific embodiment according to the present invention, in the related application of diagnosis of coronary heart disease of the invention, lncRNA includes
ENST00000444488.1 and/or uc010yfd.1；Preferably further include ASO3973, ENST00000602558.1,
One kind or more in ENST00000561165.1, RNA147299_p0403_imsncRNA819 and ENST00000415255.1
Kind.
Specific embodiment according to the present invention, in the related application of diagnosis of coronary heart disease of the invention, lncRNA includes
ENST00000444488.1.Preferably further include uc010yfd.1, ASO3973, ENST00000602558.1,
One kind or more in ENST00000561165.1, RNA147299_p0403_imsncRNA819 and ENST00000415255.1
Kind.More preferably include uc010yfd.1；Further preferably include ASO3973, ENST00000602558.1,
One kind or more in ENST00000561165.1, RNA147299_p0403_imsncRNA819 and ENST00000415255.1
Kind.
The expression of specific embodiment according to the present invention, ENST00000444488.1 increases, test individual coronary disease
Sick risk increases.
The expression of specific embodiment according to the present invention, uc010yfd.1 reduces, test individual coronary heart disease illness
Risk increases.
Specific embodiment according to the present invention, further, ASO3973, ENST00000602558.1,
The expression of ENST00000561165.1, RNA147299_p0403_imsncRNA819 and/or ENST00000415255.1
It reduces, test individual coronary heart disease risk increases.
In the more specific embodiment of the present invention, the detecting system includes detection test individual
The expression of ENST00000444488.1 and uc010yfd.1 and age, BMI, blood glucose and HDL situations.
On the other hand, the present invention also provides ENST00000444488.1 in sample of the detection from test individual is horizontal
The application in preparing detecting system for diagnosing acute myocardial infarction risk of reagent material and/or instrument and equipment；
Preferably, the expression of ENST00000444488.1 increases, test individual acute myocardial infarction risk liter
It is high.
On the other hand, the present invention also provides a kind of detecting systems of assessment incidence of coronary heart disease risk comprising：Detection comes
The reagent material and/or instrument and equipment of following lncRNA levels from the sample of test individual：
ENST00000444488.1 and/or uc010yfd.1.Preferably, lncRNA include ENST00000444488.1 and
uc010yfd.1；Preferably further include ASO3973, ENST00000602558.1, ENST00000561165.1,
It is one or more in RNA147299_p0403_imsncRNA819 and ENST00000415255.1.
The expression of specific embodiment according to the present invention, ENST00000444488.1 increases, test individual coronary disease
Sick risk increases.
Specific embodiment according to the present invention, the present invention in, the test individual be East Asia crowd, including Chinese,
Filipino, Chinese American, the Singapore nationality foreign citizen of Chinese origin, Singapore nationality Malaysian etc..When specific detection, the sample may be from
Blood, urine, saliva, gastric juice, hair or biopsy of test individual etc., preferably blood.
The expression of possible technique detection lncRNA any in this field can be used.
Specific embodiment according to the present invention, in of the invention, the reagent of the expression of the detection lncRNA
Material and/or instrument and equipment can be the expression of any feasible detection lncRNA technology in used reagent
Material and/or instrument and equipment etc..
Specific embodiment according to the present invention, the detecting system of assessment incidence of coronary heart disease risk of the invention comprising
Detection unit and assessment unit, wherein：
The detection unit includes the reagent material for the expression for detecting lncRNA described in the sample from test individual
Material and/or instrument and equipment, the testing result of the expression for obtaining test individual lncRNA；
The assessment unit includes the processing unit for carrying out assessment processing according to the testing result of detection unit.Its
In, the expression of ENST00000444488.1 increases, the expression of uc010yfd.1 declines, test individual coronary disease sufferer
Sick risk increases.
The detecting system of the assessment incidence of coronary heart disease risk of the present invention, can be virtual bench, as long as the inspection can be realized
Survey the function of unit and assessment unit.The detection unit can be include various detection reagent materials and/or inspection
Survey instrument and equipment etc.；The data analysis unit can any may be implemented to analyze the testing result of detection unit
It handles and obtains operation instrument, module or the virtual unit of coronary heart disease risk assessment situation, such as can in advance will
Various possible testing results data drawing list corresponding with corresponding risk situation formulation, by the testing result of detection unit
Incidence of coronary heart disease risk evaluation result can be obtained by compareing the data drawing list.
Using the technology of the present invention, can the targeted therapy means new to the pathogenesis of coronary heart disease and research product is provided
Pole helps.
Description of the drawings
Figure 1A-Fig. 1 D are biological express spectra differential expression lncRNA/mRNA clusterings and volcano figure.Wherein, Figure 1A：Difference
Different expression lncRNAs；Figure 1B：Differential expression mRNAs；Y-axis：The hierarchical cluster of CAD case groups and control group；X-axis：lncRNAs
With the hierarchical cluster of mRNAs expressions.The expression variation of green and the red lower reconciliation up-regulation for indicating significant difference respectively.Figure
1C：The volcanoes differential expression lncRNAs figure；Fig. 1 D：The volcanoes differential expression mRNAs figure；X-axis：log2(Fold Change)；Y-axis：
Log10 (correction P values).Red point and green point minute indicate lncRNAs or mRNAs significantly 2 times of up-regulations or downward.
Fig. 2A-Fig. 2 H show the analysis result of 7 differential expression lncRNAs of qRT-PCR repeated authentications.Wherein, Fig. 2A-figure
2G：412 coronary heart disease cases and lncRNA ENST00000444488.1, uc010yfd.1 in 295 normal healthy controls,
ASO3973, ENST00000602558.1, ENST00000561165.1, ENST00000415255.1 and RNA147299_
The expression change level of p0403_imsncRNA819；Fig. 2 H：Tables of 7 lncRNAs screened in chip and qRT-PCR
Compare up to multiple variation.Y-axis indicates that the case of log2 expresses multiple with contrast difference, and Healthy is control group, and CAD is coronary disease
Sick case group, * * indicate compared with the control group, P<0.001.
Fig. 3 A- Fig. 3 D show that ROC curve analyzes lncRNAENST00000444488.1 and uc010yfd.1 in 412 CAD
With the ROC curve areal analysis result in 295 normal healthy controls.Wherein, Fig. 3 A：The AUC of ENST00000444488.1；Fig. 3 B：
The AUC of uc010yfd.1；Fig. 3 C：The AUC that ENST00000444488.1 and uc010yfd.1 is combined；Fig. 3 D：In conjunction with the age,
The AUC of BMI, blood glucose and HDL and ENST00000444488.1 and uc010yfd.1 models.
Fig. 4 A- Fig. 4 D show 4 lncRNA areal analysis results under ROC curve in CAD.Wherein, Fig. 4 A：
The AUC results of lncRNAENST00000602558.1；Fig. 4 B：The AUC results of ASO3973；Fig. 4 C：RNA147299_p0403_
The AUC results of imsncRNA819；Fig. 4 D：The AUC results of ENST00000561165.1.
Fig. 5 A and Fig. 5 B show that lncRNAENST00000444488.1 has value of diagnosis knot to acute myocardial infarction AMI
Fruit.Wherein, Fig. 5 A：LncRNA ENST00000444488.1 expressions in patient AMI are analyzed；Fig. 5 B：lncRNA
ROC curve analyses of the ENST00000444488.1 in AMI.
Specific implementation mode
For a clearer understanding of the present invention, the present invention is further described referring now to the following example.Embodiment is only used for
It explains without limiting the invention in any way.
Test method without specific conditions is conventional method and normal condition known to fields in embodiment, or
According to the condition proposed by manufacturer.
Embodiment one
The research experiment scheme of the present embodiment includes lncRNA cDNA microarray stages and repeated authentication stage.
The 1.lncRNA cDNA microarray stages：
Coronary heart disease case and normal healthy controls totally 141 are collected, healthy group, coronary heart disease case group are divided into, are applied
AgilentlncRNA/mRNA Human Gene Expression Microarray V4.0 (4 × 180K), based on difference times
Number>2, P values<0.05, predict target gene and with the screening criterias such as CAD or dyslipidemia susceptibility loci position relationship.This hair
7 lncRNAs that differential expression in coronary heart disease is picked out in bright, as the candidate lncRNAs further verified.
2. the repeated authentication stage：
707 coronary heart disease case-control repeated authentication samples (coronary heart disease case 412, healthy control group 295) are collected,
The expression quantity of 7 candidate lncRNAs in the peripheral blood mononuclear cells (PBMCs) of case-control sample is detected using qRT-PCR,
It therefrom screens 6 lncRNAs and carries out Subject characteristics' working curve analysis (receiver operating
Characteristic curve, ROC).
3. coronary heart disease case-control study subject selects standard
This research approach is ratified by Fu Wai Hospital, Chinese Academy of Medical Sciences Ethics Committee, all people for participating in research
Group object signs informed consent form.
3.1lncRNA/mRNA chip of expression spectrum samples
Coronary heart disease case-control lncRNA/mRNA chip research samples are 141 total, are male, wherein case group 93
Example, is to go to a doctor in May, 2014 in Fu Wai Hospital, Chinese Academy of Medical Sciences and be diagnosed as the patient of coronary heart disease in January, 2011.It is strong
The healthy individuals that 48 samples of health control group are raised in June, 2014 in Shijingshan community from September, 2013.
3.2 qRT-PCR repeated authentication coronary heart disease case-control crowds
3.2.1 coronary heart disease case crowd
Case group is in January, 2011 to during in May, 2014, and Fu Wai Hospital, Chinese Academy of Medical Sciences recruits 412 CAD altogether
Patient, case group inclusion criteria are as follows：
1) inclusion criteria：
A) Han nationality, male, age are 30-70 Sui；
Last diagnostic when b) according to discharge, including acute myocardial infarction (AMI), unstable angina pectoris (UA) and stabilization
Type angina pectoris SA), underwent coronary radiography confirms, left coronary artery main stem >=50% is narrow or main narrow positions at least
70% narrow patients with coronary heart disease.Acute myocardial infarction AMI：Typical chest pain symptom, duration 30min or more, electrocardiogram have continuously
2 Lead ST elevation (limb leads >=0.1m, chest leads >=0.2mV) simultaneously have dynamic to change；Myocardial injury markers increase
And higher than 2 times, 24 hours of normal value within the scope of have dynamic evolution.Unstable angina pectoris includes initial tired type, deterioration type
And spontaneous angina.Stable angina cordis：The chest in short-term of induced generation when by movement or other increase myocardium requirementing keto quantities
Pain is broken out, and is changed with ECG ST-T section, sublingual to swallow nitroglycerin or alleviate pain.
2) exclusion criteria：
If patient has following any type situation, excluded：1) congenital heart disease；2) rheumatic valvular disease；
3) cardiomyopathy；4) apoplexy；5) diabetes；6) malignant tumour；7) disease of acute or chronic infection；8) serious liver or kidney
Dysfunction；9) secondary hypertension；10) thyroid disease；11) familial form hypercholesterolemia；12) cognition dysfunction,
Dementia patients, cacopathia；13) without signature informed consent form.
3.2.2 healthy control group crowd
295 samples of healthy control group are raised from September, 2013 in June, 2014 in Shijingshan community and Henan Province
Healthy individuals.Inclusion criteria：Age be 30-60 Sui, exclusion coronary heart disease, diabetes, heart valve disease, congenital heart disease,
It is cardiomyopathy, heart failure, secondary hypertension, cerebral apoplexy, 2 grades of hypertension or more crowd, familial hypercholesterolemia, serious
Kidney and liver diseases and thyroid disease.
4. subject's operating characteristic curve is analyzed
Subject's operation is carried out to the lncRNA expression quantity detection datas of patients with coronary artery disease and healthy control group repeated authentication
Whether characteristic (ROC) tracing analysis, the lncRNA for studying coronary heart disease differential expression can be used as the potential diagnosis biology mark of coronary heart disease
Will object.
5. experimental method
The main experimental methods used in embodiment include：
(1) separation of peripheral blood mononuclear cells (PBMCs)
1) use gradient centrifugation mode, by anticoagulated whole blood and Hank ' s liquid press 1:1 dilution proportion mixing；
2) the whole blood diluted by 2:1 ratio is slowly slowly layered on lymphocyte separation medium along centrifugation tube wall, room temperature
Lower 2800g centrifuges 20min；
3) centrifuge tube is taken out, four layers will be divided into pipe, and (upper layer is blood plasma and Hank ' s liquid, and lowest level is red blood cell and grain
Cell, middle level are lymphocyte separation medium, naked eyes visible white cloud thin layer between plasma layer and separating liquid, as rich
Containing mononuclearcell and blood platelet)；
4) after the blood plasma for sucking top layer, the mononuclearcell of plasma layer and lymphocyte separation medium interface is collected, to the greatest extent
Amount draws whole PBMCs, is transferred in new centrifuge tube；
5) 12mlHank ' s liquid is added, after even suspension cell, 2250g low-temperature centrifugation 10min discard supernatant liquid, then weigh
It is multiple primary；
6) 2250g centrifuges 3min, discards Hank ' the s liquid of upper layer remnants；
7) 1ml TRIzol are added into the PBMCs isolated, it is new to moving into one after uniformly slowly to blow and beat cell
In Eppendorf pipes of the 1.5ml without RNase, preserved in -80 DEG C of ultra low temperature freezers.
(2) cell total rna extracts
It is cracked 5 minutes using TRIzol reagents after cell cleaning, then collects cell, 100 μ l isoamyls are added in each sample
Alcohol：Chloroform (1：49) it, acutely rocks, waits for that stratification, centrifugation draw supernatant, the isometric isopropanol of supernatant is added, alcohol precipitation is produced
- 80 DEG C of object is overnight.Next day will obtain RNA precipitate after its eccentric cleaning, be dissolved in DEPC water, with Nano Drop 2000
(Thermo Scientific, USA) measures RNA concentration.
(3) genomic DNA in RNA is eliminated
Using the TURBO DNase Treatment and Removal Reagents of Life Technologies companies
Kit eliminates contaminating genomic DNA, and concrete operation step and system are as follows：
1) the RNA concentration measured according to NanoDrop 2000 calculates volume needed for 2 μ gRNA, according to as recorded in the following table 1
System configured：
Table 1
| Reagent | Dosage |
| RNA | 2μg |
| TURBO Dnase Buffer | 1.5μl |
| TURBO Dnase | 0.34μl |
| Nuclease-free water | Supply 13.2 μ l |
2) 37 DEG C of incubation 30min；
3) 1.5 μ l DNase Inactivation Reagent are added, is stored at room temperature 5min, is flicked every 1.5min mixed
Even 1 time；
4) 10000g centrifuges 90s, draws supernatant, uses NanoDrop2000 spectrophotometric determination RNA concentration.
(4) total serum IgE reverse transcription
Reverse transcription is carried out with Transcriptor First Strand cDNA (Roche, Switzerland) kit
(method is according to kit proposed standard flow operations)
1) reaction system is as recorded in the following table 2：
Table 2
| Reagent | Volume |
| RNA | 1μg |
| Transcripot RT Reaction Buffer | 4μl |
| Deoxynucleotide Mix | 2μl |
| Random Hexamer Primer | 2μl |
| Protecor RNase Inhibitor | 0.5μl |
| Transcriptor Reverse Transcriptase | 0.5μl |
| RNAase-free water | Supply 20 μ l |
2) reaction condition is as recorded in the following table 3：
Table 3
| Temperature | Time |
| 25℃ | 10min |
| 50℃ | 1h |
| 85℃ | 5min |
| 4℃ | hold |
It takes 10 μ l cDNA to carry out 4 times of dilutions, places it in -20 DEG C of preservations, remaining can be placed in -80 DEG C of Long-term Cryopreservations.
(5) real-time quantitative PCR (qRT-PCR)
LncRNA and its correlation are detected using ABI 7900T fluorescence quantitative PCR instruments (Applied Biosystems, USA)
The mRNA level in-site of gene.Take 10 μ l using 4 times of diluted cDNA as template, 3 parallel holes, GAPDH conducts is arranged in each sample
Reference gene uses 2-ΔΔCtMethod calculates mRNA relative expression levels.
Calculation formula is as follows：
Relative expression levels=2[(target gene Ct- reference gene Ct)-(control target gene Ct mean- control group reference gene Ct mean)], i.e., 2-△△Ct。
1) reaction system is as recorded in the following table 4：
Table 4
| Reagent | Volume |
| 2×Master Mix | 5μl |
| H2O | 3.6μl |
| Primers F (10 μM) | 0.2μl |
| Primer R (10 μM) | 0.2μl |
| cDNA | 1μl |
2) reaction condition is as recorded in the following table 5：
Table 5
(6) qRT-PCR primers
The primer is as recorded in the following table 6 in qRT-PCR reactions：
Table 6
(7) statistical analysis
The continuous variable of normal distribution is compared using mean between two groups of independent samples t test pair, and classified variable uses
χ2It examines, Non-Gaussian Distribution variable uses Mann-Whitney U are examined, and data normal distribution is examined using Shapiro-Wilk.
Notable GO enrichments and path analysis are accurately examined using Fisher；Between the expression patients with coronary artery disease and normal healthy controls of lncRNA
Statistical discrepancy carrys out analysis interpretation；ROC curve meter is calculated using " pROC " packet structure in R statistical softwares (Version 3.3.3)
Area is calculated, the diagnostic value of the lncRNA between patient CAD is assessed；Logistic return be used for analyze lncRNA, population characteristic with
Risk association situation between CAD；Experimental data is indicated with mean ± standard deviation (mean ± SD), with P<0.05 indicates difference
With statistical significance.
6. experimental studies results
(1) essential characteristic of study population
Biological expression spectrum chip CAD case-control sample essential characteristics are referring to table 7.
7 biological expression spectrum chip CAD case-control sample essential characteristics of table
| Variable | Healthy control group | CAD case groups | P-Value* |
| Quantity | 48 | 93 | |
| Age, year | 53±1.7 | 50±6.4 | 0.002 |
| BMI, kg/m2 | 26.0±3.2 | 26.5±3.4 | 0.402 |
| Blood glucose, mmol/L | 5.2±0.5 | 5.1±0.7 | 0.643 |
| TG, mg/dl | 151.8(93.3,229.6) | 151.3(121.2,192) | 0.490 |
| LDL, mg/ml | 95.8±29.5 | 90.9±28.8 | 0.351 |
| TC, mg/dl | 179.6±32.5 | 152.6±33.3 | <0.0001 |
| HDL, mg/ml | 51.5±14.3 | 37.3±8.7 | <0.0001 |
| Smoking, % | 89.6 | 100 | 0.004 |
| It drinks, % | 75 | 100 | <0.0001 |
Note：Continuous variable is mean ± standard deviation, and classified variable is expressed as a percentage；
BMI, body mass index；
TC, total cholesterol；
TG, triglycerides；
LDL, low-density lipoprotein；
HDL, high-density lipoprotein；
* the statistical testing results of CAD case groups and each index of healthy control group are indicated.
QRT-PCR repeated authentication CAD case-control sample essential characteristics are referring to table 8.
8 qRT-PCR repeated authentication CAD case-control sample essential characteristics of table
| Variable | Healthy control group | CAD case groups | P-Value* |
| Quantity | 295 | 412 | |
| Age, year | 50.7±12.3 | 53.4±7.8 | 0.692 |
| BMI, kg/m2 | 25.5±3.4 | 26.0±3.1 | 0.088 |
| HDL, mmol/L | 46.9±10.1 | 38.7±8.8 | <0.0001 |
| LDL, mmol/L | 101.8±25.0 | 98.5±32.1 | 0.040 |
| Blood glucose, mmol/L | 5.18±0.6 | 5.00±0.6 | <0.0001 |
| TC, mmol/L | 180.7±27.9 | 161.2±37.3 | <0.0001 |
| TG, mmol/L | 119(84.7-172.8) | 129.0(101.0-145.6) | 0.014 |
| CreA, mmol/L | 85.3±14.6 | 77.7±13.8 | <0.0001 |
| Hypertension, % | 38 | 32 | 0.144 |
| Type (AMI/UA/SA) | 290/82/40 |
Note：Continuous variable is mean ± standard deviation, and classified variable is expressed as a percentage；
BMI, body mass index；
TC, total cholesterol；
TG, triglycerides；
LDL, low-density lipoprotein；
HDL, high-density lipoprotein；
CreA, creatinine；
AMI, acute myocardial infarction AMI；
UA, unstable angina pectoris；
SA, stable angina cordis；
* the statistical testing results of CAD case groups and each index of healthy control group are indicated.
(2) chip of expression spectrum is analyzed
To change multiple>2 and P<0.05 is differential expression screening standard, and differential expression base is screened from express spectra result
Cause.Compared with the control group, lncRNAs and 890 in coronary heart disease case group difference expression gene with 1210 differential expressions
The mRNAs of differential expression；Wherein 833 lncRNAs and 427 mRNAs are significantly raised, 377 lncRNAs and 463 mRNAs
Significantly lower.Difference expression gene clustering and volcano figure are shown in Figure 1A-Fig. 1 D.Wherein, Figure 1A：Differential expression lncRNAs；Figure
1B：Differential expression mRNAs；Y-axis：The hierarchical cluster of CAD case groups and control group；X-axis：LncRNAs and mRNAs expressions
Hierarchical cluster.The expression variation of green and the red lower reconciliation up-regulation for indicating significant difference respectively.Fig. 1 C：Differential expression
The volcanoes lncRNAs figure；Fig. 1 D：The volcanoes differential expression mRNAs figure；X-axis：log2(Fold Change)；Y-axis：Log10 (correction P
Value).Red point and green point minute indicate lncRNAs or mRNAs significantly 2 times of up-regulations or downward.
(3) qRT-PCR verifies the lncRNAs of differential expression
Based on fold differences>2,P<0.05, predict target gene and with lncRNAs and CAD or the susceptible position of dyslipidemia
The screening principle such as point position relationship picks 7 lncRNAs in chip of expression spectrum analysis result and carries out repeating to test in of the invention
Card.Wherein ENST00000602558.1, ENST00000561165.1 and ENST00000415255.1 are different in coronary heart disease and blood fat
SNP susceptibility locis near often are as shown in table 9.
Table 9ENST00000602558.1, ENST00000561165.1 and ENST00000415255.1 are in coronary heart disease and blood
The extremely neighbouring susceptibility loci of fat
Using the method for qRT-PCR, 7 are verified in 412 patients with coronary heart disease and the PBMCs of 295 normal healthy controls
LncRNAs, with glyceraldehyde-3-phosphate dehydrogenase (glyceraldehyde-3-phosphate dehydrogenase, GAPDH)
As internal reference.Knot is referring to Fig. 2A-Fig. 2 H.Wherein, Fig. 2A-Fig. 2 G：412 coronary heart disease cases of qRT-PCR repeated authentications with 295
LncRNA ENST00000444488.1 in normal healthy controls, uc010yfd.1, ASO3973, ENST00000602558.1,
The expression of ENST00000561165.1, ENST00000415255.1 and RNA147299_p0403_imsncRNA819 change water
It is flat；Fig. 2 H：7 lncRNAs screened of the present invention are in chip compared with the expression multiple variation in qRT-PCR.Y-axis indicates
The case of log2 expresses multiple with contrast difference, and Healthy is control group, and CAD is coronary heart disease case group, and * * are indicated and control group
It compares, P<0.001.The results show that in expression trend of 7 lncRNAs in large sample repeated authentication result and chip data
Expression trend be consistent (Fig. 2 H), wherein ENST00000444488.1 is significantly increased to 2.6 times of (P in CAD groups PBMCs
<0.01), uc010yfd.1, ASO3973, ENST00000602558.1, ENST00000561165.1, RNA147299_
P0403_imsncRNA819 and ENST00000415255.1 is remarkably decreased in CAD groups PBMCs respectively to 37%, 81%,
79%, 87%, 83% and 65% (Fig. 2A-Fig. 2 G, P<0.01), due to the Ct values of ENST00000415255.1>30, follow-up
Follow-up study will not be included into research.
(4) the new lncRNA biomarkers of identification coronary heart disease
A) the diagnostic of 6 lncRNAs of ROC curve assay
With ROC curve evaluation ENST00000444488.1, uc010yfd.1, ASO3973,
ENST00000602558.1, ENST00000561165.1 and RNA147299_p0403_imsncRNA819 diagnosis of coronary heart disease
Efficiency.Area (Area under the ROC curve, AUC) is shown in Fig. 3 A- Fig. 3 D and figure under the ROC curve of 6 lncRNAs
4A- Fig. 4 D.Wherein, Fig. 3 A：The AUC of ENST00000444488.1；Fig. 3 B：The AUC of uc010yfd.1；Fig. 3 C：
The AUC that ENST00000444488.1 and uc010yfd.1 is combined；Fig. 3 D：In conjunction with age, BMI, blood glucose and HDL and
The AUC of ENST00000444488.1 and uc010yfd.1 models.Fig. 4 A：LncRNAENST00000602558.1 ROC in CAD
Area under the curve result；Fig. 4 B：The AUC results of ASO3973；Fig. 4 C：RNA147299_p0403_imsncRNA819；Fig. 4 D：
The AUC results of ENST00000561165.1.
ENST00000602558.1, ASO3973, RNA147299_p0403_imsncRNA819 and
The AUC of ENST00000561165.1 is respectively 0.625 (0.581-0.669), 0.639 (0.595-0.682), 0.625
(0.582-0.668) and 0.599 (0.555-0.644) (Fig. 4 A- Fig. 4 B), diagnostic is relatively low.
The AUC of ENST00000444488.1 and uc010yfd.1 is respectively 0.799 (0.762-0.837) and 0.779
(0.744-0.815) (Fig. 3 A- Fig. 3 B).The AUC for combining ENST00000444488.1 and uc010yfd.1 is 0.851 (0.819-
0.884), sensitivity 0.707, specificity are 0.844 (Fig. 3 C), are higher than the AUC of any single lncRNA, therefore 2
The combination of lncRNA has higher diagnosis of coronary artery disease, lncRNA biomarkers that can be new as coronary heart disease.Into one
Step combines 2 lncRNAs markers with tetra- age, BMI, blood glucose and HDL common risk factors, and AUC reaches 0.902
(0.876-0.928), susceptibility 0.736, specificity is 0.922 (Fig. 3 D), therefore the model has higher diagnostic.
B) lncRNAENST00000444488.1 can be used as the biomarker of identification AMI
Fig. 5 A and Fig. 5 B show that lncRNAENST00000444488.1 there is diagnostic value to divide acute myocardial infarction AMI
Analyse data.
It is compared with 112 non-AMI patients, ENST00000444488.1 is expressed in 290 AMI patients and is significantly increased to
1.5 times of (P<0.001) (Fig. 5 A).
The present invention further applies the efficiency of ROC curve assay ENST00000444488.1 diagnosis AMI.As a result it shows
Show that its AUC is 0.758 (0.716-0.800), susceptibility 0.632, specificity is 0.773 (Fig. 5 B), is shown
ENST00000444488.1 has the efficiency of diagnosis AMI.
Sequence table
<110>Fu Wai Hospital, Chinese Academy of Medical Sciences
<120>Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application
<130> GAI18CN3440
<160> 52
<170> PatentIn version 3.5
<210> 1
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 1
gatcccaagt atggcagaag gat 23
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 2
agtccttggc aacctccaaa 20
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 3
tcaaaaggcc ttgatcccga 20
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 4
aaggactctg cttcatgggt g 21
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 5
agcaggtaag tcatctggaa gga 23
<210> 6
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 6
catcaggact ctgaaagcaa ctgt 24
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 7
caacttttct gtgggccgtg 20
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 8
ggcgaggtgt gtcagattca 20
<210> 9
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 9
tgtccattaa atagaaccag caatg 25
<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 10
ttggtgcaca gtgatttttt tctt 24
<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 11
accgcgctct gtagcttagg 20
<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 12
gcgtggtagc ttgcattttg 20
<210> 13
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 13
ctggttggtc agtgatatct gtagatc 27
<210> 14
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 14
gccagaggat gggttatctt tataat 26
<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 15
ctgctgtggt tgctcccatt ac 22
<210> 16
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 16
cacctgcaca ttctcagtgg ga 22
<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 17
gaatacgcag atgagaggct acg 23
<210> 18
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 18
cgtcataaca caccgatttc tgat 24
<210> 19
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 19
gagggaggat agagccaagt ac 22
<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 20
agtcactgtg ctcagaccat cc 22
<210> 21
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 21
gctacaagca gaagtgacca agg 23
<210> 22
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 22
ggtcaggtgt aggttctgag ag 22
<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 23
ccaagtttgg caaccgcaac gt 22
<210> 24
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 24
agtaggagct gtcggagtct ga 22
<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 25
agaacctcct gttccttcag cg 22
<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 26
gttccgaact tttgactgtc agc 23
<210> 27
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 27
ggtgatgtgg atgctctatg gg 22
<210> 28
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 28
tctccaacct caaagagcag gg 22
<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 29
catgcagaga tgtgcctcca ca 22
<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 30
tcagagaagc ggcagtcaca ct 22
<210> 31
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 31
gtctttgact ccttgctgaa tctg 24
<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 32
cacctcatcg tcttccaagc ac 22
<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 33
gtttcacctg cgtgatgtgc ca 22
<210> 34
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 34
ggctggcata ataggctcct tg 22
<210> 35
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 35
caggaagaca gagtgtgctg gt 22
<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 36
aattggacgg cggttcatcc ct 22
<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 37
gaatctactg gtctgacctg tcc 23
<210> 38
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 38
ggtccagtag atgttgctgt gg 22
<210> 39
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 39
ggagcgagat ccctccaaaa t 21
<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 40
ggctgttgtc atacttctca tgg 23
<210> 41
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 41
actcacctct tcagaacgaa ttg 23
<210> 42
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 42
ccatctttgg aaggttcagg ttg 23
<210> 43
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 43
gagagtgatt gagagtggac cac 23
<210> 44
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 44
cacaaccctc tgcacccagt tt 22
<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 45
tgtatgtgac tgcccaagat gaag 24
<210> 46
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 46
agaggaggtt ggtctcacta cc 22
<210> 47
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 47
ccacagacct tccaggagaa tg 22
<210> 48
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 48
gtgcagttca gtgatcgtac agg 23
<210> 49
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 49
agcggctgac gtgtgccagt aat 23
<210> 50
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 50
tctgagacct ctggcttcgt ca 22
<210> 51
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 51
attctgtgcc ccacagtaag gc 22
<210> 52
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223>Primer
<400> 52
tggtcacaga gccaccttct tg 22
Claims (10)
- Applications of the lncRNA below 1. as the biomarker of diagnosis of coronary heart disease：ENST00000444488.1 and/or uc010yfd.1.
- 2. the reagent material and/or instrument and equipment that detect lncRNA levels in the sample from test individual are being prepared for diagnosing Application in the detecting system of coronary heart disease risk, the lncRNA include：ENST00000444488.1 and/or uc010yfd.1.
- 3. application according to claim 2, wherein lncRNA levels include expression in peripheral blood mononuclear cells.
- 4. application according to claim 2, wherein lncRNA further comprise ASO3973, ENST00000602558.1, One kind or more in ENST00000561165.1, RNA147299_p0403_imsncRNA819 and ENST00000415255.1 Kind.
- 5. application according to claim 2, wherein lncRNA includes ENST00000444488.1；Include preferably further uc010yfd.1；Still more preferably include ASO3973, ENST00000602558.1, ENST00000561165.1, RNA147299_ It is one or more in p0403_imsncRNA819 and ENST00000415255.1.
- 6. application according to claim 2, wherein the expression of ENST00000444488.1 increases, test individual hat Worry risk increases.
- 7. application according to claim 2, wherein the expression of uc010yfd.1 reduces, test individual coronary disease sufferer Sick risk increases.
- 8. application according to claim 2, wherein the detecting system includes detection test individual The expression of ENST00000444488.1 and uc010yfd.1 and age, BMI, blood glucose and HDL situations.
- 9. the reagent material and/or instrument and equipment of ENST00000444488.1 levels exist in sample of the detection from test individual Prepare the application in the detecting system for diagnosing acute myocardial infarction risk；Preferably, the expression of ENST00000444488.1 increases, and test individual acute myocardial infarction risk increases.
- 10. a kind of detecting system of assessment incidence of coronary heart disease risk comprising：It detects following in the sample from test individual The reagent material and/or instrument and equipment of lncRNA levels：ENST00000444488.1 and/or uc010yfd.1；The expression of ENST00000444488.1 increases, and the expression of uc010yfd.1 reduces, test individual coronary disease sufferer Sick risk increases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810637044.3A CN108774641A (en) | 2018-06-20 | 2018-06-20 | Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810637044.3A CN108774641A (en) | 2018-06-20 | 2018-06-20 | Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108774641A true CN108774641A (en) | 2018-11-09 |
Family
ID=64026119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810637044.3A Pending CN108774641A (en) | 2018-06-20 | 2018-06-20 | Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108774641A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110059103A1 (en) * | 2007-09-10 | 2011-03-10 | Ericus Anna Leonardus Biessen | Future cardiac event biomarkers |
| CN106550605A (en) * | 2014-03-18 | 2017-03-29 | 汉诺威医学院 | For the mitochondria non-coding RNA of progression of disease in predicting heart failure and Patients With Myocardial Infarction |
| WO2017068198A1 (en) * | 2015-10-23 | 2017-04-27 | Academisch Medisch Centrum | Biomarker for predicting coronary artery disease in smokers |
| CN107653312A (en) * | 2017-09-07 | 2018-02-02 | 中国医学科学院阜外医院 | The rs7901016 detecting system related to blood lipid level and coronary heart disease and related application |
-
2018
- 2018-06-20 CN CN201810637044.3A patent/CN108774641A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110059103A1 (en) * | 2007-09-10 | 2011-03-10 | Ericus Anna Leonardus Biessen | Future cardiac event biomarkers |
| CN106550605A (en) * | 2014-03-18 | 2017-03-29 | 汉诺威医学院 | For the mitochondria non-coding RNA of progression of disease in predicting heart failure and Patients With Myocardial Infarction |
| WO2017068198A1 (en) * | 2015-10-23 | 2017-04-27 | Academisch Medisch Centrum | Biomarker for predicting coronary artery disease in smokers |
| CN107653312A (en) * | 2017-09-07 | 2018-02-02 | 中国医学科学院阜外医院 | The rs7901016 detecting system related to blood lipid level and coronary heart disease and related application |
Non-Patent Citations (1)
| Title |
|---|
| LIN LI等: "Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease", 《ATHEROSCLEROSIS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170053617A (en) | Methods for Evaluating Lung Cancer Status | |
| JP2009529880A (en) | Primary cell proliferation | |
| JP2008521412A (en) | Lung cancer prognosis judging means | |
| CN109477145A (en) | The biomarker of inflammatory bowel disease | |
| KR102110039B1 (en) | Biomarker microRNA-26b or microRNA-4449 for diagnosing obesity and use thereof | |
| CN110205378B (en) | Vertebral column tuberculosis plasma miRNA combined diagnosis marker and application thereof | |
| WO2011044927A1 (en) | A method for the diagnosis or prognosis of an advanced heart failure | |
| US20190185937A1 (en) | Rna editing as biomarkers for mood disorders test | |
| US20210214807A1 (en) | Method and kit for the diagnosis of colorectal cancer | |
| JP2023157965A (en) | Method for detecting atopic dermatitis | |
| CN113234817B (en) | Marker for detecting early liver cancer by using CpG locus methylation level | |
| CN108774641A (en) | Coronary heart disease lncRNA expression spectrum discrimination identification biomarkers and related application | |
| WO2021230379A1 (en) | Method for detecting parkinson disease | |
| CN108165546A (en) | A kind of miRNA biomarker, composition and application thereof | |
| CN111108199B (en) | Biomarkers for atherosclerotic cardiovascular disease | |
| WO2020111169A1 (en) | Genetic testing method for multifactorial genetic disease and testing kit | |
| KR101583417B1 (en) | Snps for diagnosing asprin-exacerbated respiratory disease and the method for providing information required for diagnosing the same using snps | |
| Zhao et al. | Verification of expression of LINC00648 in the serum of lung cancer patients by TCGA database | |
| CN116287252B (en) | Application of long-chain non-coding RNA APCDD1L-DT in preparation of pancreatic cancer detection products | |
| WO2024062867A1 (en) | Method for analyzing possibility of cancer developing in subject | |
| TWI676688B (en) | The cell type identification method and system thereof | |
| KR102110038B1 (en) | Biomarker let-7a or let-7f for diagnosing obesity and use thereof | |
| McHenry | Genomic and Co-Evolutionary Determinants of Clinical Severity in Active Tuberculosis Patients | |
| JP2023073135A (en) | Method for detecting severity of menopausal disorders | |
| WO2022186296A1 (en) | Method for detecting deterioration in severity of atopic dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181109 |
|
| WD01 | Invention patent application deemed withdrawn after publication |